Undurraga A, Meneses M, Oyarzún M
Servicio de Medicina INERyCT, Anatomía Patológica Hospital del Salvador, Facultad de Medicina, Universidad de Chile.
Rev Med Chil. 1997 Jun;125(6):690-5.
There are few reports on the use of cyclosporine in idiopathic pulmonary fibrosis, in experimental animals or humans. We report three patients with advanced pulmonary fibrosis in whom steroid therapy failed and that received cyclosporine in a dose of 3 to 5 mg/kg for three to five months. One patient developed systemic hypertension that subsided reducing the dose of cyclosporine. No positive changes in dyspnea were obtained and pulmonary function tests deteriorated during the treatment period. We conclude that cyclosporine treatment had no clinical benefit in these patients with pulmonary fibrosis.
关于环孢素在特发性肺纤维化患者、实验动物或人类中的应用报道很少。我们报告了3例晚期肺纤维化患者，他们接受了3至5毫克/千克剂量的环孢素治疗3至5个月，之前的类固醇治疗均告失败。其中1例患者出现全身性高血压，在减少环孢素剂量后血压消退。治疗期间呼吸困难没有明显改善，肺功能测试结果恶化。我们得出结论，环孢素治疗对这些肺纤维化患者没有临床益处。
